Eloisa Ruiz

Eloisa Ruiz

Auto-generated profile, based on publicly available information

Eloisa Ruiz

Department of Thoracic Surgery and Lung Transplantation, University Hospital Reina Sofía, 14004 Córdoba, Spain

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 April 2021 in PLOS ONE
Verified
Journal Article
Open access
PDF file
FGFrancisco Javier Gonzalez
Francisco Javier Gonzalez
EAEnriqueta Alvarez
Enriqueta Alvarez
PMPaula Moreno
Paula Moreno
DPDavid Poveda
David Poveda
EREloisa Ruiz
Eloisa Ruiz
AÁAntonio Álvarez-Kindelán
Antonio Álvarez-Kindelán
Objective: To determine whether problems arising in the native lung may influence the short-term outcomes and survival after single lung transplantation (SLT), and therefore should be taken into consideration when selecting the transplant procedure. Patients and methods: Retrospective review of 258 lung transplants performed between June 2012 and June 2019. Among them, 161 SLT were selected for the analysis. Complications in the native lung were recorded and distributed into two groups: early and late complications (within 30 days or after 30 days post-transplant). Donor and recipient preoperative factors, 30-day mortality and survival were analysed and compared between groups by univariable and multivariable analyses, and adjusting for transplant indication. Results: There were 161 patients (126M/35F; 57±7 years) transplanted for emphysema (COPD) (n = 72), pulmonary fibrosis (IPF) (n = 77), or other indications (n = 12). Forty-nine patients (30%) presented complications in the native lung. Thirty-day mortality did not differ between patients with or without early complications (6% vs. 12% respectively; p = 0.56). Twelve patients died due to a native lung complication (7.4% of patients; 24% of all deaths). Survival (1,3,5 years) without vs. with late complications: COPD (89%, 86%, 80% vs. 86%, 71%, 51%; p = 0.04); IPF (83%, 77%, 72% vs. 93%, 68%, 58%; p = 0.65). Among 30-day survivors: COPD (94%, 91%, 84% vs. 86%, 71%, 51%; p = 0.01); IPF (93%, 86%, 81% vs. 93%, 68%, 58%; p = 0.19). Native lung complications were associated to longer ICU stay (10±17 vs. 33±96 days; p<0.001), longer postoperative intubation (41±85 vs. 99±318 hours; p = 0.006), and longer hospital stay (30±24 vs. 45±34 days; p = 0.03). The presence of late native lung problems predicted survival in COPD patients (OR: 2.55; p = 0.07). Conclusion: The native lung is a source of morbidity in the short-term and mortality in the long-term after lung transplantation. This should be taken into consideration when choosing the transplant procedure, especially in COPD patients.

23 April 2023 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
AFAnna Muñoz Fos
Anna Muñoz Fos
PMPaula Moreno
Paula Moreno
FGFrancisco Javier González
Francisco Javier González
EREloisa Ruiz
Eloisa Ruiz
JVJose Manuel Vaquero
Jose Manuel Vaquero
AÁAntonio Álvarez-Kindelán
Antonio Álvarez-Kindelán
(1) Objective: To determine whether recent advances in lung transplantation (LT) have reduced the incidence and changed the risk factors for airway complications (AC). (2) Methods: Retrospective analysis of patients receiving a lung transplant between January 2007 and January 2019. An AC was defined as a bronchoscopic abnormality in the airway, either requiring or not requiring an endoscopic or surgical intervention. Both univariable and multivariable analyses were performed to identify risk factors for AC. (3) Results: 285 lung transplants (170 single and 115 bilateral lung transplants) were analysed, comprising 400 anastomoses at risk. A total of 50 anastomoses resulted in AC (12%). There were 14 anastomotic and 11 non-anastomotic stenoses, 4 dehiscences, and 3 malacias. Independent predictors for AC were: gender male (OR: 4.18; p = 0.002), cardiac comorbidities (OR: 2.74; p = 0.009), prolonged postoperative mechanical ventilation (OR: 2.5; p = 0.02), PaO2/FiO2 < 300 mmHg at 24 h post-LT (OR: 2.48; p = 0.01), graft infection (OR: 2.16; p = 0.05), and post-LT isolation of Aspergillus spp. (OR: 2.63; p = 0.03). (4) Conclusions: In spite of advances in lung transplantation practice, the risk factors, incidence, and lethality of AC after LT remains unchanged. Graft dysfunction, an infected environment, and the need of prolonged mechanical ventilation remain an Achilles heel for AC.

1 March 2020 in Transplantation Proceedings
Verified
Journal Article
Closed access
ELEloísa Ruiz López
Eloísa Ruiz López
FMFrancisco Cerezo Madueño
Francisco Cerezo Madueño
FGFrancisco Javier González Garcia
Francisco Javier González Garcia
AFAnna Muñoz Fos
Anna Muñoz Fos
DCDavid Poveda Chávez
David Poveda Chávez
PCPaula Moreno Casado
Paula Moreno Casado

7 August 2023 in Cancers
Verified
Journal Article
Open access
PDF file
EREloisa Ruiz
Eloisa Ruiz
PMPaula Moreno
Paula Moreno
FGFrancisco Javier Gonzalez
Francisco Javier Gonzalez
AGAlba María Fernández González
Alba María Fernández González
BCBenito Cantador
Benito Cantador
AÁAntonio Álvarez-Kindelán
Antonio Álvarez-Kindelán
(1) Background: Malignancies are an important cause of mortality after solid organ transplantation. The purpose of this study was to analyze the incidence of malignancies in patients receiving lung transplants (LT) and their influence on patients’ survival. (2) Methods: Review of consecutive LT from 1994 to 2021. Patients with and without malignancies were compared by univariable and multivariable analyses. Survival was compared with Kaplan-Meier and Cox regression analysis. (3) Results: There were 731 LT malignancies developed in 91 patients (12.4%) with related mortality of 47% (n = 43). Native lung cancer, digestive and hematological malignancies were associated with higher lethality. Malignancies were more frequent in males (81%; p = 0.005), transplanted for emphysema (55%; p = 0.003), with cyclosporine-based immunosuppression (58%; p < 0.001), and receiving single LT (65%; p = 0.011). Survival was worse in patients with malignancies (overall) and with native lung cancer. Risk factors for mortality were cyclosporine-based immunosuppression (OR 1.8; 95%CI: 1.3–2.4; p < 0.001) and de novo lung cancer (OR 2.6; 95%CI: 1.5–4.4; p < 0.001). (4) Conclusions: Malignancies are an important source of morbidity and mortality following lung transplantation that should not be neglected. Patients undergoing single LT for emphysema are especially at higher risk of mortality due to lung cancer in the native lung.

1 July 2021 in Open Respiratory Archives
Verified
Journal Article
Open access
ELEloísa Ruiz López
Eloísa Ruiz López
FGF. Javier Gónzalez García
F. Javier Gónzalez García
PCPaula Moreno Casado
Paula Moreno Casado
CPCarlos M. Villar Pasto
Carlos M. Villar Pasto
DCDavid Sebastián Poveda Chávez
David Sebastián Poveda Chávez
AKAntonio Álvarez Kindelán
Antonio Álvarez Kindelán